| scholarly article | Q13442814 |
| P50 | author | Jari Tiihonen | Q38639394 |
| Fabian Hoti | Q41171286 | ||
| Ellenor Mittendorfer-Rutz | Q87020102 | ||
| P2093 | author name string | Amy Leval | |
| Antti Tanskanen | |||
| Heidi Taipale | |||
| Erik Jedenius | |||
| Juha Mehtälä | |||
| Dana Enkusson | |||
| Jan Sermon | |||
| Maila Majak | |||
| P2860 | cites work | Medication for attention deficit-hyperactivity disorder and criminality | Q24619697 |
| Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis | Q28293647 | ||
| Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis | Q28303010 | ||
| 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). | Q34018491 | ||
| A meta-analysis of the efficacy of second-generation antipsychotics | Q34534321 | ||
| Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies | Q34545159 | ||
| Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study | Q34873532 | ||
| The effect of clozapine on premature mortality: an assessment of clinical monitoring and other potential confounders | Q35369635 | ||
| Antipsychotic treatment and mortality in schizophrenia | Q35369872 | ||
| Agreement between PRE2DUP register data modeling method and comprehensive drug use interview among older persons | Q36175497 | ||
| Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features | Q37227479 | ||
| Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial | Q37341552 | ||
| Association Between Prescription of Major Psychotropic Medications and Violent Reoffending After Prison Release | Q37401454 | ||
| Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials | Q37451403 | ||
| Comparative effectiveness and safety of antipsychotic drugs in schizophrenia treatment: a real-world observational study | Q39610094 | ||
| Mortality and Cumulative Exposure to Antipsychotics, Antidepressants, and Benzodiazepines in Patients With Schizophrenia: An Observational Follow-Up Study | Q40228281 | ||
| Real-world effectiveness of antipsychotics | Q42374185 | ||
| Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study | Q43246864 | ||
| Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study | Q44695213 | ||
| Antipsychotics and mortality in first-onset schizophrenia: prospective Finnish register study with 5-year follow-up | Q48436615 | ||
| Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia | Q48685001 | ||
| A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. | Q55054009 | ||
| Selection Bias in Clinical Trials With Antipsychotics | Q57847856 | ||
| Factors associated with relapse in schizophrenia despite adherence to long-acting injectable antipsychotic therapy | Q87452749 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| P304 | page(s) | 686-693 | |
| P577 | publication date | 2017-07-01 | |
| P1433 | published in | JAMA Psychiatry | Q635830 |
| P1476 | title | Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia | |
| P478 | volume | 74 |
| Q60641225 | A genome-wide association study in individuals of African ancestry reveals the importance of the Duffy-null genotype in the assessment of clozapine-related neutropenia |
| Q91901138 | A retrospective study of the role of long-acting injectable antipsychotics in preventing rehospitalization in early psychosis with cannabis use |
| Q89494311 | Adding Suicide Prevention to the Triple Advantages of Injectable Long-Acting Second-Generation Antipsychotics |
| Q89715622 | Antipsychotic Medications and DNA Methylation in Schizophrenia and Bipolar Disorder: A Systematic Review |
| Q47586829 | Antipsychotic polypharmacy prescribing and risk of hospital readmission |
| Q64238772 | Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia |
| Q90310120 | Attitudes of European physicians towards the use of long-acting injectable antipsychotics |
| Q92972180 | Clinical risk model to predict 28-day unplanned readmission via the accident and emergency department after discharge from acute psychiatric units for patients with psychotic spectrum disorders |
| Q90215001 | Community perceptions of barriers to management of chronic psychotic disorders and knowledge and attitudes about long-acting injectable antipsychotic medication: qualitative study in Dar es Salaam, Tanzania |
| Q47258573 | Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia-A Nationwide Study With 20-Year Follow-up |
| Q91102341 | Decriminalization in action: lessons from the Los Angeles model |
| Q89828559 | Development and Validation of a Machine Learning Individualized Treatment Rule in First-Episode Schizophrenia |
| Q47225222 | Economic evaluation of paliperidone palmitate once monthly for treating chronic schizophrenia patients in the United Arab Emirates |
| Q60919880 | Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting |
| Q102210892 | Effectiveness of antipsychotic drugs in schizophrenia: a 10-year retrospective study in a Korean tertiary hospital |
| Q57074533 | Effects of long-acting injectable antipsychotics versus oral antipsychotics on autonomic nervous system activity in schizophrenic patients |
| Q90731688 | Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting |
| Q60920949 | Evaluation of oral antipsychotic supplementation of select second-generation long-acting injectable antipsychotics in an acute-care psychiatric setting |
| Q58803803 | Factors associated with first- versus second-generation long-acting antipsychotics prescribed under ordinary clinical practice in Italy |
| Q92978714 | Health and work disability outcomes in parents of patients with schizophrenia associated with antipsychotic exposure by the offspring |
| Q90485876 | Heterogeneity of Treatment Effects of Long-Acting Injectable Antipsychotic Medications |
| Q91774747 | Hospitalisation and length of hospital stay following first-episode psychosis: systematic review and meta-analysis of longitudinal studies |
| Q90173301 | Hospitalization Rates and Therapy Costs of German Schizophrenia Patients Who are Initiated on Long-Acting Injectable Medication: A Mirror-Image Study |
| Q90186939 | Improving the "real life" management of schizophrenia spectrum disorders by LAI antipsychotics: A one-year mirror-image retrospective study in community mental health services |
| Q91235917 | Increased schizophrenia family history burden and reduced premorbid IQ in treatment-resistant schizophrenia: a Swedish National Register and Genomic Study |
| Q88963662 | Letter to the Editor: Is paliperidone palmitate more effective than other long-acting injectable antipsychotics? |
| Q52641201 | Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents. |
| Q42687636 | Long-acting injectable antipsychotics for prevention and management of violent behaviour in psychotic patients |
| Q54217848 | Long-acting injectable antipsychotics update: lengthening the dosing interval and expanding the diagnostic indications. |
| Q55282197 | Long-term treatment with clozapine and verbal memory performance in schizophrenia. |
| Q88884687 | Measuring adherence to antipsychotic medications for schizophrenia: Concordance and validity among a community sample in rural China |
| Q98891298 | Mesenchymal stem cells derived extracellular vesicles improve behavioral and biochemical deficits in a phencyclidine model of schizophrenia |
| Q58570501 | Neural circuitry and precision medicines for mental disorders: are they compatible? |
| Q91905904 | Patients' experiences of long-acting injectable antipsychotics: a qualitative study |
| Q64068715 | Personalizing antipsychotic treatment: evidence and thoughts on individualized tailoring of antipsychotic dosage in the treatment of psychotic disorders |
| Q47743073 | Pharmacotherapy of mood disorders and psychosis in pre- and post-natal women |
| Q92695687 | Psychosis breakthrough on antipsychotic maintenance: results from a nationwide study |
| Q53272906 | Real-world Effectiveness of Pharmacologic Treatments for the Prevention of Rehospitalization in a Finnish Nationwide Cohort of Patients With Bipolar Disorder. |
| Q57825240 | Real-world effectiveness of long-acting antipsychotic treatments in a nationwide cohort of 3957 patients with schizophrenia, schizoaffective disorder and other diagnoses in Quebec |
| Q92757906 | Real-world effectiveness of long-acting injections for reducing recurrent hospitalizations in patients with schizophrenia |
| Q47626801 | Recovery and serious mental illness: a review of current clinical and research paradigms and future directions. |
| Q64277226 | Risk of readmission in patients with schizophrenia and schizoaffective disorder newly prescribed clozapine |
| Q50027178 | Simplifying medication administration: From daily ingestion to monthly injection |
| Q91802418 | Suicide in Schizophrenia: An Educational Overview |
| Q97420463 | The Impact of Mental Illness Stigma on Psychiatric Emergencies |
| Q57480545 | The Lancet Commission on global mental health and sustainable development |
| Q92032782 | The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness |
| Q57817726 | The acute efficacy of antipsychotics in schizophrenia: a review of recent meta-analyses |
| Q90391485 | The effectiveness of long-acting injectable antipsychotics versus oral antipsychotics in the maintenance treatment of outpatients with chronic schizophrenia |
| Q93333373 | The effects of different periods of co-administration of oral and long-acting injectable aripiprazole: A propensity score analysis |
| Q89842585 | The use of long-acting Aripiprazole in a multi-center, prospective, uncontrolled, open-label, cohort study in Germany: a report on global assessment of functioning and the WHO wellbeing index |
| Q60441606 | Treatment resistant schizophrenia – review and a call to action |
| Q97587444 | Undetectable or subtherapeutic serum levels of antipsychotic drugs preceding switch to clozapine |
| Q55023835 | What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? |
| Q92014619 | [Long-acting antipsychotics: The QAAPAPLE algorithm review] |
Search more.